Wells Fargo’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-5,658
Closed -$339K 7910
2021
Q1
$339K Sell
5,658
-638
-10% -$23.1K ﹤0.01% 4900
2020
Q4
$94K Buy
6,296
+4,222
+204% +$58.7K ﹤0.01% 5388
2020
Q3
$24K Buy
+2,074
New +$35.4K ﹤0.01% 5714

Wells Fargo's PAND Position: Q2 2021 in Review

Wells Fargo sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 5,658 shares — an estimated $339K sold.

Wells Fargo first reported a position in PAND in Q3 2020 and held it in 3 quarters. The position peaked at $339K in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

  • Wells Fargo reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Wells Fargo sold 5,658 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $339K.
  • Wells Fargo first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Wells Fargo's Pandion Therapeutics Inc. Common Stock position peaked at $339K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on Wells Fargo's 13F filing for Q2 2021, filed 16 Aug 2021.